Cochrane · systematic review · CD004760

Creatine for treating muscle disorders

Kley, RA, Tarnopolsky, MA, Vorgerd, M · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library

Neuromuscular2 versionsAMSTAR 2: not assessed

SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.

Questions

current version

GRADE rated

No studies

Included studies

No studies 0 · 0%Ungraded 3 · 23.1%Very low 0 · 0%Low 0 · 0%Moderate 1 · 7.7%High 9 · 69.2%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Show all 2 versions

Creatine for treating muscular dystrophies

Population: patients with muscular dystrophies

5 questions

Outcome	Effect	Evidence	Status / GRADE
Maximum voluntary contraction in dystrophinopathies %	no estimate extracted	3 studies · 121 participants	High
Maximum voluntary contraction in myotonic dystrophy type 1 %	no estimate extracted	2 studies · 76 participants	Moderate Downgraded: inconsistency
Maximum voluntary contraction in myotonic dystrophy type 2 %	no estimate extracted	1 study · 10 participants	High
Adverse events	no estimate extracted	8 studies · 261 participants	High
Global assessment of improvement felt better	RR 4.51 [2.33, 8.74]	4 studies · 183 participants	High

Creatine for treating metabolic myopathies

Population: patients with metabolic myopathies

5 questions

Outcome	Effect	Evidence	Status / GRADE
Maximum voluntary contraction in mitochondrial diseases %	no estimate extracted	2 studies · 38 participants	High
Maximum voluntary contraction in glycogen storage disease type V %	no estimate extracted	1 study · 28 participants	High
Impairment of activities of daily living (ADL) in glycogen storage disease type V Visual numeric scale. Scale from: 1 to 10.	no estimate extracted	1 study · 19 participants	High
Adverse events in mitochondrial diseases	no estimate extracted	3 studies · 38 participants	Ungraded
Adverse events in glycogen storage disease type V	no estimate extracted	2 studies · 28 participants	Ungraded

Creatine for treating idiopathic inflammatory myopathies

Population: patients with idiopathic inflammatory myopathies

3 questions

Outcome	Effect	Evidence	Status / GRADE
Aggregate functional performance time (AFPT), intention‐to‐treat analysis %	no estimate extracted	1 study · 37 participants	High
AFPT, valid compliant completer analysis %	no estimate extracted	1 study · 29 participants	High
Adverse events	no estimate extracted	1 study · 37 participants	Ungraded